The earnings call highlighted significant positive developments, including successful trial results, strong financial positioning, and positive feedback from stakeholders. Despite a reported net loss and increased expenses, the overall sentiment remains optimistic due to the strategic advancements and preparations for upcoming trials.

Company Guidance -

Q3 2025

During the Trevi Therapeutics Second Quarter 2025 Earnings Conference Call, the company provided several key metrics regarding their financial and clinical progress. Trevi reported a net loss of $12.3 million for the second quarter of 2025, slightly down from $12.4 million in the same quarter of 2024. The company's cash and investments totaled approximately $204 million as of June 30, 2025, bolstered by a public offering in June that raised around $115 million. This financial position is expected to support their operational activities into 2029, including two Phase III trials for IPF-related chronic cough, a planned trial for non-IPF interstitial lung disease cough, and their next RCC trial. Clinically, Trevi highlighted positive data from the CORAL trial, noting a statistically significant reduction in cough frequency and marked improvements in quality of life scores. The company plans to initiate Phase III trials in the first half of 2026 and has several Phase I studies underway.

Successful CORAL Trial Results

Trevi's CORAL trial for chronic cough in IPF patients met its primary endpoint with statistically significant reductions in 24-hour cough frequency across all dose groups. The Leicester Cough Questionnaire showed marked improvement, with significant increases of 3.7 and 3.4 points for the 54 and 108 mg BID doses, respectively.

Strong Financial Position

Trevi raised approximately $115 million in capital, resulting in a total cash and investments of around $204 million by the end of June 2025, providing a financial runway into 2029.

Phase III Program Planning

Trevi is preparing to initiate Phase III trials for chronic cough in IPF patients in the first half of next year, along with studies for non-IPF interstitial lung diseases and refractory chronic cough.

Positive Stakeholder Feedback

Patient advisory board feedback indicated that the results from the CORAL trial could significantly impact and improve patients' daily lives.

Trevi Therapeutics (TRVI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

TRVI Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.10 / -	-0.13	―	―	―
Aug 07, 2025	2025 (Q2)	-0.10 / -0.09	-0.12	25.00% (+0.03)	―
May 08, 2025	2025 (Q1)	-0.12 / -0.09	-0.11	18.18% (+0.02)	―
Mar 18, 2025	2024 (Q4)	-0.13 / -0.11	-0.08	-37.50% (-0.03)	―
Nov 06, 2024	2024 (Q3)	-0.12 / -0.13	-0.08	-62.50% (-0.05)	―
Aug 08, 2024	2024 (Q2)	-0.11 / -0.12	-0.07	-71.43% (-0.05)	―
May 07, 2024	2024 (Q1)	-0.09 / -0.11	-0.06	-83.33% (-0.05)	―
Mar 20, 2024	2023 (Q4)	-0.09 / -0.08	-0.06	-33.33% (-0.02)	―
Nov 09, 2023	2023 (Q3)	-0.09 / -0.08	-0.12	33.33% (+0.04)	―
Aug 10, 2023	2023 (Q2)	-0.09 / -0.07	-0.14	50.00% (+0.07)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

TRVI Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 07, 2025	$7.30	$7.42	+1.64%
May 08, 2025	$6.60	$6.60	0.00%
Mar 18, 2025	$6.56	$6.81	+3.81%
Nov 06, 2024	$3.10	$2.90	-6.45%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Trevi Therapeutics Inc (TRVI) report earnings?

Trevi Therapeutics Inc (TRVI) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Trevi Therapeutics Inc (TRVI) earnings time?

Trevi Therapeutics Inc (TRVI) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is TRVI EPS forecast?

TRVI EPS forecast for the fiscal quarter 2025 (Q3) is -0.1.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing